Structural analysis of the interaction between human cytokine BMP-2 and the antagonist Noggin reveals molecular details of cell chondrogenesis inhibition.

Noggin X-ray crystallography bone morphogenetic protein (BMP) cell differentiation chondrogenesis protein folding protein structure protein-protein interaction recombinant protein expression site-directed mutagenesis

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
02 2023
Historique:
received: 19 09 2022
revised: 04 01 2023
accepted: 06 01 2023
pubmed: 16 1 2023
medline: 25 2 2023
entrez: 15 1 2023
Statut: ppublish

Résumé

Bone morphogenetic proteins (BMPs) are secreted cytokines belonging to the transforming growth factor-β superfamily. New therapeutic approaches based on BMP activity, particularly for cartilage and bone repair, have sparked considerable interest; however, a lack of understanding of their interaction pathways and the side effects associated with their use as biopharmaceuticals have dampened initial enthusiasm. Here, we used BMP-2 as a model system to gain further insight into both the relationship between structure and function in BMPs and the principles that govern affinity for their cognate antagonist Noggin. We produced BMP-2 and Noggin as inclusion bodies in Escherichia coli and developed simple and efficient protocols for preparing pure and homogeneous (in terms of size distribution) solutions of the native dimeric forms of the two proteins. The identity and integrity of the proteins were confirmed using mass spectrometry. Additionally, several in vitro cell-based assays, including enzymatic measurements, RT-qPCR, and matrix staining, demonstrated their biological activity during cell chondrogenic and hypertrophic differentiation. Furthermore, we characterized the simple 1:1 noncovalent interaction between the two ligands (K

Identifiants

pubmed: 36642181
pii: S0021-9258(23)00024-8
doi: 10.1016/j.jbc.2023.102892
pmc: PMC9929448
pii:
doi:

Substances chimiques

Bone Morphogenetic Protein 2 0
Cytokines 0
Transforming Growth Factor beta 0
BMP2 protein, human 0
noggin protein 148294-77-3
Carrier Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102892

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest F. K. is research associate of the FRS-FNRS (Brussels, Belgium). The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Charly Robert (C)

Laboratory of Enzymology and Protein Folding, University of Liège, Liège, Belgium; Centre for Protein Engineering, InBioS Research Unit, University of Liège, Liège, Belgium.

Frédéric Kerff (F)

Centre for Protein Engineering, InBioS Research Unit, University of Liège, Liège, Belgium; Biological Macromolecule Crystallography, University of Liège, Liège, Belgium.

Fabrice Bouillenne (F)

Centre for Protein Engineering, InBioS Research Unit, University of Liège, Liège, Belgium.

Maxime Gavage (M)

Analytical Laboratory, CER Groupe, rue du Point du Jour, Marloie, Belgium.

Marylène Vandevenne (M)

Laboratory of Enzymology and Protein Folding, University of Liège, Liège, Belgium; Centre for Protein Engineering, InBioS Research Unit, University of Liège, Liège, Belgium.

Patrice Filée (P)

Laboratory of immuno-biology, CER Groupe, Novalis Science Park, Aye, Belgium.

André Matagne (A)

Laboratory of Enzymology and Protein Folding, University of Liège, Liège, Belgium; Centre for Protein Engineering, InBioS Research Unit, University of Liège, Liège, Belgium. Electronic address: amatagne@uliege.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH